Shabir A Madhi

Professor of Vaccinology, University of the Witwatersrand Director: MRC Respiratory and Meningeal Pathogens Research Unit

## Virus: A "non-living" infective agent, only able to multiply in living cells of a host.



- Mainly droplet spread transmission:
  - possibly direct inoculation.
  - Self-inoculation following contact with contaminated surfaces.
- Exact numbers infected unknown, since sensitive to who is tested (bias against asymptomatic and mild illness).
- □ Reproductive rate of ~2.5 and case fatality rate 1-2%.
- **Expect "herd immunity" once approximately one-third of population are infected.**

# What to expect from SARS-CoV-2, which causes COVID-19.



- 20-80% asymptomatic (carrying virus but not ill).
- Of the symptomatic (fever or respiratory symptoms),10-15% with severe illness.
- Approximately 5% require ventilation/ICU
- Case fatality risks 1-2% (variable based on denominator); and differ with co-morbidities.

# Global burden of COVID-19: 3 April 020

# Coronavirus Cases: 1,030,633

Deaths:

# 54,229

Recovered: 220,003

Geographic distribution of cumulative number of reported COVID-19 cases per 100 000 population, worldwide, as of 26 March 2020



# Country distribution of COVID-19 cases (29 March 2020)

The number of confirmed cases is lower than the number of total cases; due to limited and/or restrictive testing criteria.

Country, Other 1	Total Cases ↓	Copy	Look U	Jp Sha	re ,ered ↓↑	Active Cases ↓↑	Serious, Critical ↓↑	Tot Cases/ 1M pop ↓↑	Deaths/ 1M pop ↓1	Case fatality risl (CFR) (26 Mar)
World	1,030,633	+15,568	54,229	+1,062	220,003	756,401	38,178	132.2	7.0	1.5%
<u>USA</u>	245,442	+565	6,098	+28	10,411	228,933	5,421	742	18	10.2%
<u>Spain</u>	117,710	+5,645	10,935	+587	30,513	76,262	6,416	2,518	234	4.5%
Italy	115,242		13,915		18,278	83,049	4,053	1,906	230	7.6%
<u>Germany</u>	85,063	+269	1,111	+4	22,440	61,512	3,936	1,015	13	5.9%
<u>China</u>	81,620	+31	3,322	+4	76,571	1,727	379	57	2	7.6% 5.8%
France	59,105		5,387		12,428	41,290	6,399	905	83	1.6%
Iran	53,183	+2,715	3,294	+134	17,935	31,954	4,035	633	39	5.0%
<u>UK</u>	33,718		2,921		135	30,662	163	497	43	1.5%
Switzerland	19,303	+476	573	+37	4,846	13,884	348	2,230	66	5.8%
									_	

• Case fatality risk (CFR) does not account for cases still under treatment (may be higher)

- Differences in threshold for investigating will influence CFR.
- Differences in population demographic and co-morbidities affect attack rate and CFR

# Country distribution of COVID-19 cases (3 Apr 2020)

Country, Other ↓↑	Total Cases ↓	New Cases ↓↑	Total Deaths ↓1	New Deaths ↓↑	Total Recovered ↓↑	Active Cases ↓↑	Serious, Critical ↓↑	Tot Cases/ 1M pop ↓↑	Deaths/ 1M pop ↓↑
South Africa	1,462		5		95	1,362	7	25	0.08
Peru	1,414		55		537	822	51	43	2
Dominican Republic	1,380		60		16	1,304	147	127	6
Iceland	1,319		4		284	1,031	12	3,865	12
Argentina	1,265		37	+1	256	972		28	0.8
Serbia	1,171		31		42	1,098	81	134	4
Colombia	1,161		19		55	1,087	50	23	0.4
Singapore	1,114	+65	5	+1	266	843	24	190	0.9
UAE	1,024		8		96	920	2	104	0.8
Croatia	1,011		7		88	916	34	246	2
<u>Algeria</u>	986				61	839		22	2

## Risk for infection similar across age-group, but older individuals more susceptible to fatal outcome.

in Data

#### Coronavirus: early-stage case fatality rates by Our World age-group in China

Case fatality rate (CFR) is calculated by dividing the total number of deaths from a disease by the number of confirmed c----Data is based on early-stage analysis of the COVID-19 outbreak in China in the period up to February 11, 2020.



Data source: Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological of	characteristics of an outbreak of 2019 novel coronavirus
diseases (COVID-19)China, 2020. China CDC Weekly.	
OurWorldinData.org – Research and data to make progress against the world's largest problems.	Licensed under CC-BY by the authors.

OurWorldinData.org - Research and data to make progress against the world's largest problems.

PRE-EXISTING CONDITION	DEATH RATE confirmed cases	DEATH RATE all cases
Cardiovascular disease	13.2%	10.5%
Diabetes	9.2%	7.3%
Chronic respiratory disease	8.0%	6.3%
Hypertension	8.4%	6.0%
Cancer	7.6%	5.6%
no pre-existing conditions		0.9%

### **Case fatality risk:**

- **?HIV (7 million) and TB (300,000)** •
- Seasonal influenza 40-fold increased risk mortality in PLWH

## Covid-19 cases as of 2 April 2020 in South Africa



- Biases in terms of select group tested.
- Majority of testing in private sector and using algorithm geared toward detecting imported cases and their contacts.
- Emergence of "sporadic cases", including health care workers- indicating community transmission.
- Current figures an under-estimate of burden of COVID-19 in SA, yet doubling time of three days.

# Covid-19 cases as of 29 March 2020 in South Africa

GAUTENG	584
WESTERN CAPE	310
KWAZULU – NATAL	167
FREE STATE	72
NORTH WEST	6
MPUMALANGA	11
LIMPOPO	12
EASTERN CAPE	12
NORTHERN CAPE	6
UNALLOCATED	100

- Biases in terms of select group tested.
- Majority of testing in private sector and using algorithm geared toward detecting imported cases and their contacts.
- Emergence of "sporadic cases", including health care workers- indicating community transmission.
- Current figures an under-estimate of burden of COVID-19 in SA, yet doubling time of three days.

# Doubling time of 3-4 days in number of COVID-19 cases, despite very restrictive threshold for testing.



- Projection based on restrictive testing algorithm, and no intervention.
- Expect acceleration in number of cases with change in criteria for testing (i.e. irrespective of travel or contact.
  - Likely reduction in doubling time to 24 hours.
- Change in demographics and outcome with changes in testing algorithm.

Spatial distribution of COVID-19 cases in Johannesburg: Absence off identifying cases ≠ absence of disease

The number of confirmed cases is lower than the number of total cases; due to limited and/or restrictive testing criteria.



City of Joburg Corona Virus Disease (COVID19) Situational Report, as on 20th March 2020



Urgent need for scaling up of testing facilities, with low threshold for indication for testing across the country, and especially in major metro in Gauteng, WC, KZN.



#### Source: Morgan Stanley, Johns Hopkins CSSE

### Where are we in the epidemic???



# South Korea cases



Currently Infected

# South Korea cases



### "Countries can't simply lock down their societies to defeat coronavirus"





Mike Ryan, WHO, Assistant Director General for Emergencies

"What we really need to focus on is finding those who are sick, those who have the virus, and isolate them, find their contacts and isolate them".

"The danger right now with the lockdowns ... if we don't put in place the strong public health measures now, when those movement restrictions and lockdowns are lifted, the danger is the disease will jump back up."

# What to expect from the lockdown

### Free-for-all



Moderate distancing



### Attempted quarantine/lockdown



Extensive distancing



https://www.washingtonpost.com/graphics/2020/world/corona-simulator/

# Considerations

- Duration of lockdown?
- □ Implication of residual circulation of SARS-CoV-2, post lockdown
- □ Social distancing and other precautionary/preventative measures
- **Role of higher institutions in supporting Government response**
- Implications for academic year in higher education
- Community mobilisation at multiple fronts

# Priority areas for action

- Scaling up Country-wide Diagnostic Capacity
- Safety and Protection of Frontline Healthcare Personnel
- Increase Access to Mandatory Influenza Vaccination
- Centralized and Decentralised Containment Areas
- Enhance Clinical Care Capacity
- Systems Management and Logistic Support for Public Hospitals
- Immediate Private- Public Healthcare Partnership Agreement
- Psychological Preparedness and Support for Frontline Healthcare Personnel.
- Community mobilisation at multiple fronts